Houston, TX 的 神經膠質瘤 臨床試驗
23 項針對 神經膠質瘤 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
招募中1/2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Baylor College of Medicine, Houston
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
招募中1 期
- M D Anderson Cancer Center, Houston
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
招募中2 期
- Texas Children's Hospital, Houston
MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
招募中
- M D Anderson Cancer Center, Houston
Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
招募中觀察性研究
- M D Anderson Cancer Center, Houston
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
招募中1 期
- The University of Texas M. D. Anderson Cancer Center, Houston
Targeted Pediatric High-Grade Glioma Therapy
招募中觀察性研究
- Texas Children's Hospital, Houston
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Study of Olutasidenib and Temozolomide in HGG
招募中2 期
- Texas Children's Hospital, Houston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- MD Anderson Cancer Center, Houston
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
招募中2 期
- Texas Children's Hospital, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
招募中觀察性研究
- M D Anderson Cancer Center, Houston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
招募中1/2 期
- Research Site, Houston
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
招募中1 期
- Excel Diagnostics & Nuclear Oncology Center, Houston
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
招募中1 期
- Texas Children's Hospital, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- University of Texas MD Anderson Cancer Center, Houston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
招募中早期第 1 期歡迎健康志工
- Texas Children's Hospital, Houston
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
招募中早期第 1 期
- M D Anderson Cancer Center, Houston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
招募中2 期
- Texas Children's Hospital, Houston
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
招募中早期第 1 期
- Texas Children's Hospital, Houston
其他城市的 神經膠質瘤 試驗
- New York City, NY25 項研究
- Boston, MA20 項研究
- Washington, DC19 項研究
- Philadelphia, PA16 項研究
- Columbus, OH15 項研究
- Miami, FL15 項研究
- San Francisco, CA14 項研究
- Chicago, IL13 項研究
- Durham, NC12 項研究
- Seattle, WA11 項研究
- Los Angeles, CA10 項研究
- St. Louis, MO10 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。